Works by Bays, Harold E.

Results: 52

Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.

Published in:

Cardiology, 2016, v. 135, n. 1, p. 3, doi. 10.1159/000445047

By:

Kastelein, John J.P.;
Hallén, Jonas;
Vige, Runar;
Fraser, David a.;
Zhou, Rong;
Hustvedt, Svein Olaf;
Orloff, David G.;
Bays, Harold E.

Publication type:

Article

Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 5, p. 868, doi. 10.1111/dom.14645

By:

Leiter, Lawrence A.;
Banach, Maciej;
Catapano, Alberico L.;
Duell, P. Barton;
Gotto, Antonio M.;
Laufs, Ulrich;
Mancini, G. B. John;
Ray, Kausik K.;
Hanselman, Jeffrey C.;
Ye, Zhan;
Bays, Harold E.

Publication type:

Article

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.

Published in:

European Journal of Preventive Cardiology, 2020, v. 27, n. 6, p. 593, doi. 10.1177/2047487319864671

By:

Ballantyne, Christie M;
Laufs, Ulrich;
Ray, Kausik K;
Leiter, Lawrence A;
Bays, Harold E;
Goldberg, Anne C;
Stroes, Erik SG;
MacDougall, Diane;
Zhao, Xin;
Catapano, Alberico L

Publication type:

Article

Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.

Published in:

JAMA Network Open, 2022, v. 5, n. 1, p. e2141898, doi. 10.1001/jamanetworkopen.2021.41898

By:

Mozaffarian, Dariush;
Maki, Kevin C.;
Bays, Harold E.;
Aguilera, Fernando;
Gould, Glenn;
Hegele, Robert A.;
Moriarty, Patrick M.;
Robinson, Jennifer G.;
Shi, Peilin;
Tur, Josefina F.;
Lapointe, Jean-François;
Aziz, Sarya;
Lemieux, Pierre

Publication type:

Article

Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus.

Published in:

International Journal of General Medicine, 2014, v. 7, p. 355, doi. 10.2147/ijgm.s65148

By:

Bays, Harold E.

Publication type:

Article

Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial.

Published in:

2017

By:

Hollander, Priscilla;
Bays, Harold E.;
Rosenstock, Julio;
Frustaci, Mary Ellen;
Fung, Albert;
Vercruysse, Frank;
Erondu, Ngozi

Publication type:

journal article

Individualizing Treatment with Statin Therapy.

Published in:

2018

By:

Bays, Harold Edward;
Cobble, Michael;
Bays, Harold E

Publication type:

journal article

Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study.

Published in:

Obesity (19307381), 2025, v. 33, n. 3, p. 500, doi. 10.1002/oby.24240

By:

Ard, Jamy D.;
Ryan, Donna H.;
O'Neil, Patrick M.;
Kushner, Robert F.;
Wyatt, Holly R.;
Bays, Harold E.;
Greenway, Frank L.;
Jakicic, John M.;
Leonard, Sharon;
Kenan, Yael;
Ganon‐Elazar, Eti;
Wadden, Thomas A.

Publication type:

Article

Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.

Published in:

2020

By:

Bays, Harold E.;
Kozlovski, Plamen;
Shao, Qing;
Proot, Pieter;
Keefe, Deborah

Publication type:

journal article

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus.

Published in:

Obesity (19307381), 2014, v. 22, n. 4, p. 1042, doi. 10.1002/oby.20663

By:

Bays, Harold E.;
Weinstein, Richard;
Law, Gordon;
Canovatchel, William

Publication type:

Article

Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials.

Published in:

2017

By:

Bays, Harold E.;
Leiter, Lawrence A.;
Colhoun, Helen M.;
Thompson, Desmond;
Bessac, Laurence;
Pordy, Robert;
Toth, Peter P.

Publication type:

journal article

Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins: Study Design and Rationale of a Phase III Clinical Programme.

Published in:

Clinical Drug Investigation, 2008, v. 28, n. 10, p. 625, doi. 10.2165/00044011-200828100-00003

By:

Jones, Peter H.;
Bays, Harold E.;
Davidson, Michael H.;
Kelly, Maureen T.;
Buttler, Susan M.;
Setze, Carolyn M.;
Sleep, Darryl J.;
Stolzenbach, James C.

Publication type:

Article

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.

Published in:

Vascular Health & Risk Management, 2015, v. 11, p. 165, doi. 10.2147/VHRM.S70907

By:

Bays, Harold E.;
Brinton, Eliot A.;
Triscari, Joseph;
Chen, Erluo;
Maccubbin, Darbie;
MacLean, Alexandra A.;
Gibson, Kendra L.;
Ruck, Rae Ann;
Johnson-Levonas, Amy O.;
O'Neill, Edward A.;
Mitchel, Yale B.

Publication type:

Article

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.

Published in:

2015

By:

Bays, Harold E;
Brinton, Eliot A;
Triscari, Joseph;
Chen, Erluo;
Maccubbin, Darbie;
MacLean, Alexandra A;
Gibson, Kendra L;
Ruck, Rae Ann;
Johnson-Levonas, Amy O;
O'Neill, Edward A;
Mitchel, Yale B

Publication type:

journal article

The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia.

Published in:

Diabetes Care, 2010, v. 33, n. 9, p. 2113, doi. 10.2337/dc10-0357

By:

BAYS, HAROLD E.;
ROTH, ELI M.;
MCKENNEY, JAMES M.;
KELLY, MAUREEN T.;
THAKKER, KAMLESH M.;
SETZE, CAROLYN M.;
OBERMEYER, KATIE;
SLEEP, DARRYL J.

Publication type:

Article

Consistency of Extended-Release Niacin/ Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups.

Published in:

2012

By:

Bays, Harold E.;
Shah, Arvind;
Lin, Jianxin;
Sisk, Christine McCrary;
Qian Dong;
Maccubbin, Darbie

Publication type:

Journal Article

Consistency of Extended-Release Niacin/ Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups.

Published in:

American Journal of Cardiovascular Drugs, 2012, v. 12, n. 3, p. 197, doi. 10.2165/11631530-000000000-00000

By:

Bays, Harold E.;
Shah, Arvind;
Lin, Jianxin;
Sisk, Christine McCrary;
Qian Dong;
Maccubbin, Darbie

Publication type:

Article

Bempedoic Acid for Prevention of Cardiovascular Events in People With Obesity: A CLEAR Outcomes Subset Analysis.

Published in:

Journal of the American Heart Association, 2025, v. 14, n. 4, p. 1, doi. 10.1161/JAHA.124.037898

By:

Bays, Harold E.;
Bloedon, LeAnne;
Brennan, Danielle;
Lei Lei;
Lincoff, A. Michael;
Nicholls, Stephen J.;
Plutzky, Jorge;
Powell, Heather A.;
Nissen, Steven E.

Publication type:

Article

Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid.

Published in:

2022

By:

Ballantyne, Christie M.;
Bays, Harold E.;
Louie, Michael J.;
Smart, Jeremy;
Yang Zhang;
Ray, Kausik K.;
Zhang, Yang

Publication type:

journal article

A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.

Published in:

Journal of the American Heart Association, 2022, v. 11, n. 6, p. 1, doi. 10.1161/JAHA.121.024176

By:

Maki, Kevin C.;
Bays, Harold E.;
Ballantyne, Christie M.;
Underberg, James A.;
Kastelein, John J. P.;
Johnson, Judith B.;
Ferguson, James J.

Publication type:

Article

A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.

Published in:

2022

By:

Maki, Kevin C;
Bays, Harold E;
Ballantyne, Christie M;
Underberg, James A;
Kastelein, John J P;
Johnson, Judith B;
Ferguson, James J

Publication type:

journal article

Long-term (52–78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients.

Published in:

Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy, 2012, v. 5, p. 125, doi. 10.2147/DMSO.S32018

By:

Bays, Harold E.

Publication type:

Article

Colesevelam, Ezetimibe, and Patients With Type 2 Diabetes Mellitus: Characteristics and Clinical Outcomes From a Health Care Database.

Published in:

2014

By:

Swindle, Jason P.;
Xin Ye;
Mallick, Rajiv;
Song, Rui;
Horstman, Thomas;
Bays, Harold E.;
Ye, Xin

Publication type:

journal article

MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin.

Published in:

Journal of Clinical Endocrinology & Metabolism, 2011, v. 96, n. 9, p. 2889, doi. 10.1210/jc.2011-1061

By:

Bays, Harold E.;
Schwartz, Sherwyn;
Littlejohn III, Thomas;
Kerzner, Boris;
Krauss, Ronald M.;
Karpf, David B.;
Yun-Jung Choi;
Xueyan Wang;
Sue Naim;
Roberts, Brian K.

Publication type:

Article

Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development.

Published in:

Expert Review of Cardiovascular Therapy, 2011, v. 9, n. 3, p. 265, doi. 10.1586/ERC.10.22

By:

Bays, Harold E.

Publication type:

Article

Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.

Published in:

Expert Review of Cardiovascular Therapy, 2009, v. 7, n. 11, p. 1429, doi. 10.1586/ERC.09.123

By:

Bays, Harold E.

Publication type:

Article

Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.

Published in:

Expert Review of Cardiovascular Therapy, 2009, v. 7, n. 7, p. 1429, doi. 10.1586/erc.09.123

By:

Bays, Harold E.

Publication type:

Article

Ezetimibe: cholesterol lowering and beyond.

Published in:

Expert Review of Cardiovascular Therapy, 2008, v. 6, n. 4, p. 447, doi. 10.1586/14779072.6.4.447

By:

Bays, Harold E.;
Neff, David;
Tomassini, Joanne E.;
Tershakovic, Andrew M.

Publication type:

Article

Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinica implications.

Published in:

Expert Review of Cardiovascular Therapy, 2008, v. 6, n. 3, p. 391, doi. 10.1586/14779072.6.3.391

By:

Bays, Harold E.;
Tighe, Ann P.;
Sadovsky, Richard;
Davidson, Michael H.

Publication type:

Article

Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.

Published in:

Expert Review of Cardiovascular Therapy, 2008, v. 6, n. 3, p. 343, doi. 10.1586/14779072.6.3.343

By:

Bays, Harold E.;
Michael, J.;
González-Campoy;
Bray, George A.;
Kitabchi, Abbas E.;
Bergman, Donald A.;
Schorr, Alan Bruce;
Rodbard, Helena W.;
Henry, Robert R.

Publication type:

Article

Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.

Published in:

Metabolic Syndrome & Related Disorders, 2015, v. 13, n. 6, p. 239, doi. 10.1089/met.2014.0137

By:

Bays, Harold E.;
Ballantyne, Christie M.;
Braeckman, Rene A.;
Stirtan, William G.;
Doyle, Ralph T.;
Philip, Sephy;
Soni, Paresh N.;
Juliano, Rebecca A.

Publication type:

Article

Effects of Coadministered Ezetimibe Plus Fenofibrate in Mixed Dyslipidemic Patients with Metabolic Syndrome.

Published in:

Metabolic Syndrome & Related Disorders, 2011, v. 9, n. 2, p. 135, doi. 10.1089/met.2010.0068

By:

Bays, Harold E.;
Shah, Arvind;
Macdonell, Geraldine;
Taggart, William V.;
Gumbiner, Barry

Publication type:

Article

Anthropometric Measurements and Diabetes Mellitus: Clues to the “Pathogenic” and “Protective” Potential of Adipose Tissue.

Published in:

Metabolic Syndrome & Related Disorders, 2010, v. 8, n. 4, p. 307, doi. 10.1089/met.2009.0089

By:

Harold E. Bays;
Kathleen M. Fox;
Susan Grandy

Publication type:

Article

Current and Investigational Antiobesity Agents and Obesity Therapeutic Treatment Targets.

Published in:

Obesity (19307381), 2004, v. 12, n. 8, p. 1197, doi. 10.1038/oby.2004.151

By:

Bays, Harold E.

Publication type:

Article

Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemia.

Published in:

Current Medical Research & Opinion, 2008, v. 24, n. 4, p. 1179, doi. 10.1185/030079908X280527

By:

Harold E. Bays;
Richard H. Chapman;
Kathleen M. Fox;
Susan Grandy

Publication type:

Article

Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States

Published in:

Current Medical Research & Opinion, 2007, v. 23, n. 9, p. 2125, doi. 10.1185/030079907X219580

By:

Kathleenm M. Fox;
Sanjay K. Gandhi;
Robert L. Ohsfeldt;
James W. Blasetto;
Harold E. Bays

Publication type:

Article

Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus.

Published in:

2007

By:

Bays HE;
Cohen DE;
Bays, Harold E;
Cohen, David E

Publication type:

journal article

Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus.

Published in:

Current Medical Research & Opinion, 2007, v. 23, n. 7, p. 1673, doi. 10.1185/030079907X210525

By:

Harold E. Bays;
David E. Cohen

Publication type:

Article

Effects of Omega-3-acid Ethyl Esters on LDL Particle Size in Subjects with Hypertriglyceridcmia Despite Statin Therapy.

Published in:

FASEB Journal, 2007, v. 21, n. 5, p. A108

By:

Maki, Kevin C.;
Davidson, Michael H.;
Bays, Harold E.;
Stein, Evan A.;
Shalwitz, Robert A.;
Doyle, Ralph

Publication type:

Article

Effectiveness of Rosuvastatin in LDL-C Lowering and National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Goal Attainment Compared to Other Statins Among Diabetes Patients.

Published in:

Diabetes, 2007, v. 56, p. A620

By:

Fox, Kathleen M.;
Gandhi, Sanjay K.;
Ohsfeldt, Robert L.;
Blasetto, James;
Bays, Harold E.

Publication type:

Article

Effect of Colesevelam HCl on Glycemic Control in Type 2 Diabetic Subjects Receiving Metformin Monotherapy.

Published in:

Diabetes, 2007, v. 56, p. A129

By:

Bays, Harold E.;
Goldberg, Ronald B.;
Truitt, Kenneth;
Dmuchowski, Carl;
Jones, Michael

Publication type:

Article

Efficacy and Safety of Alirocumab as Add-on Therapy in High-Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies

Published in:

Clinical Cardiology, 2014, v. 37, n. 10, p. 597, doi. 10.1002/clc.22327

By:

Robinson, Jennifer G.;
Colhoun, Helen M.;
Bays, Harold E.;
Jones, Peter H.;
Du, Yunling;
Hanotin, Corinne;
Donahue, Stephen

Publication type:

Article

Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects.

Published in:

Clinical Cardiology, 2006, v. 29, n. 6, p. 268, doi. 10.1002/clc.4960290609

By:

Davidson, Michael H.;
Bays, Harold E.;
Stein, Evan;
Maki, Kevin C.;
Shalwitz, Robert A.;
Doyle, Ralph

Publication type:

Article

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study.

Published in:

Cardiology & Therapy, 2019, v. 8, n. 1, p. 79, doi. 10.1007/s40119-019-0131-8

By:

Ballantyne, Christie M.;
Manku, Mehar S.;
Bays, Harold E.;
Philip, Sephy;
Granowitz, Craig;
Doyle, Ralph T.;
Juliano, Rebecca A.

Publication type:

Article

Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model.

Published in:

Fundamental & Clinical Pharmacology, 2015, v. 29, n. 2, p. 209, doi. 10.1111/fcp.12096

By:

Bays, Harold E.;
Chen, Erluo;
Tomassini, Joanne E.;
McPeters, Gail;
Polis, Adam B.;
Triscari, Joseph

Publication type:

Article

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.

Published in:

JAMA: Journal of the American Medical Association, 2024, v. 331, n. 1, p. 38, doi. 10.1001/jama.2023.24945

By:

Aronne, Louis J.;
Sattar, Naveed;
Horn, Deborah B.;
Bays, Harold E.;
Wharton, Sean;
Lin, Wen-Yuan;
Ahmad, Nadia N.;
Zhang, Shuyu;
Liao, Ran;
Bunck, Mathijs C.;
Jouravskaya, Irina;
Murphy, Madhumita A.

Publication type:

Article

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.

Published in:

Cardiovascular Diabetology, 2013, v. 12, n. 1, p. 1, doi. 10.1186/1475-2840-12-100

By:

Brinton, Eliot A.;
Ballantyne, Christie M.;
Bays, Harold E.;
Kastelein, John J.;
Braeckman, Rene A.;
Soni, Paresh N.

Publication type:

Article

Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.

Published in:

2019

By:

Vijayaraghavan, Krishnaswami;
Szerlip, Harold M.;
Ballantyne, Christie M.;
Bays, Harold E.;
Philip, Sephy;
Doyle, Ralph T.;
Juliano, Rebecca A.;
Granowitz, Craig;
Doyle, Ralph T Jr

Publication type:

journal article

Proactive and Progressive Approaches in Managing Obesity.

Published in:

2016

By:

Eckel, Robert H.;
Bays, Harold E.;
Klein, Samuel;
Bade Horn, Deborah

Publication type:

journal article

Raisins compared with other snack effects on glycemia and blood pressure: a randomized, controlled trial.

Published in:

2014

By:

Anderson, James W;
Weiter, Kathy M;
Christian, Amber L;
Ritchey, Michelle B;
Bays, Harold E

Publication type:

Journal Article